Breast cancer is considered the most common
malignancy, with the profound ability to perform a wide range of metabolic reprogramming. Within the
breast cancer microenvironment, highly available
cancer-associated adipocytes interact with
cancer cells by releasing various
adipocytokines and metabolites.
Obesity is also an important factor in this manner, where the accumulation of adipose tissue next to
tumor tissue is linked to the increased incidence, progression, and
metastasis of
breast cancer. The metabolic changes caused by the crosstalk between
breast cancer cells and dysfunctional adipose tissue include
glucose,
lipid, and
amino acid metabolism. Thus, preventing this interaction between
breast cancer cells and dysfunctional adipose tissue might develop a promising therapeutic strategy against
breast cancer. This review focused on the metabolic changes responsible for inducing the crosstalk between
breast cancer cells and adipocytes. We also reviewed the recent updates in
therapeutics designed to disrupt this interaction.